Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 38, 2019 - Issue 5
112
Views
4
CrossRef citations to date
0
Altmetric
Case Report

Recurrent natural killer/T-cell lymphoma of the lacrimal sac and nasolacrimal duct in a 59-year-old Caucasian woman

, , &
Pages 428-431 | Received 31 Aug 2018, Accepted 07 Nov 2018, Published online: 05 Dec 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Elzbieta Mechel, Ann. Q. Tran, Victoria S. North, Farnoush M. Moen & Andrea A. Tooley. (2022) Natural killer T-cell lymphoma causing bilateral recurrent recalcitrant dacryocystitis. Orbit 41:6, pages 766-770.
Read now
Swati Singh & Mohammad Javed Ali. (2020) Lymphoproliferative tumors involving the lacrimal drainage system: a major review. Orbit 39:4, pages 276-284.
Read now

Articles from other publishers (2)

Vamsee K. Neerukonda, Anna M. Stagner & Natalie Wolkow. (2021) Lymphoma of the Lacrimal Sac: The Massachusetts Eye and Ear Experience With a Comparison to the Previously Reported Literature. Ophthalmic Plastic & Reconstructive Surgery 38:1, pages 79-86.
Crossref
Jessica Y. Tong, Valerie Juniat & Dinesh Selva. (2021) Radiological Features of Small Lymphocytic Lymphoma Involving the Lacrimal Sac. Ophthalmic Plastic & Reconstructive Surgery 37:5, pages 502-504.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.